πŸ‡ΊπŸ‡Έ FDA
Patent

US 12036256

Adoptive cellular therapy

granted A61KA61K2039/5256A61K35/763

Quick answer

US patent 12036256 (Adoptive cellular therapy) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K2039/5256, A61K35/763, A61K40/10, A61K40/31